GynTools

AI-based Diagnostic Solution for Women's Health

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in August 2016 by Nimrod Lev, Ahinoam Lev Sagie, and Meny Lev Sagie, GynTools operates with 1–10 employees. The company has raised $4.38 million across nine funding rounds. In June 2024, GynTools was recognized with the 2024 'Rising Startup' Asper Prize at Hebrew University.

Business overview

GynTools develops GYNI, an AI-based rapid point-of-care diagnostic system designed to address the high misdiagnosis rates of vaginitis, a common gynecological issue. The company's product is AMAR & CE approved and has commenced commercialization in Israel and Europe, with plans for US FDA submission. GynTools operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Medical Diagnostics, and serves healthcare providers and women consumers globally.

Strategic signal

In June 2024, GynTools received the 'Rising Startup' Asper Prize at Hebrew University. This recognition highlights the company's innovative approach to women's health diagnostics and signals strong academic and industry validation of its AI-based solution, positioning GynTools as a notable emerging player in the femtech and digital health landscape.

Company Intelligence Q&A

What significant recognition did GynTools receive in June 2024?
In June 2024, GynTools was awarded the 2024 'Rising Startup' Asper Prize at Hebrew University, acknowledging its innovative contributions to the startup ecosystem.
What strategic support did GynTools secure in May 2024?
In May 2024, GynTools received a grant from the Google AI Startup Fund, indicating strategic support for its AI-driven diagnostic solutions.
When did GynTools secure its most recent private equity funding round?
GynTools secured a Seed funding round in March 2025.
What is GynTools' core product and its current market status?
GynTools' core product is GYNI, an AI-based diagnostic system for vaginitis. It is AMAR & CE approved and has begun commercialization in Israel and Europe, with preparations underway for US FDA submission.
What was a notable early grant received by GynTools?
In January 2018, GynTools received a grant from the Jerusalem Development Authority.